In-vitro Diagnostics (IVD) Reagents Market Research 2025-2030: Innovation and Intensified Competition Drive Growth Amid Rising Demand for Early Diagnosis and Personalized Medicine

The global In-vitro Diagnostics (IVD) Reagents Market is set to grow from USD 77.56 billion in 2024 to USD 96.17 billion by 2030, at a CAGR of 3.65%. Key trends include biomarker discovery, POC testing, and AI automation. North America leads the market, with major players like Abbott, Danaher, and Roche driving innovation.
In-vitro Diagnostics (IVD) Reagents Market
Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "In-vitro Diagnostics (IVD) Reagents Market - Global Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.The In-vitro Diagnostics (IVD) Reagents Market was valued at USD 77.56 Billion in 2024, and is projected to reach USD 96.17 Billion by 2030, rising at a CAGR of 3.65%
The report considers the present scenario of the global IVD reagents market and its market dynamics for 2025-2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
The global IVD reagents market is highly competitive and dynamic within the broader medical diagnostics industry. As healthcare systems increasingly rely on early disease detection, personalized medicine, and point-of-care testing, the demand for reliable and innovative IVD reagents has surged. This demand has led to intensified competition among global players, characterized by innovation, strategic alliances, aggressive market expansion, and pricing pressure.
Furthermore, as consumer demand for convenience grows, companies in the IVD reagents market will compete to develop user-friendly, self-testing kits that offer lab-quality results at home. Companies will increasingly focus on targeted diagnostics for specific populations, diseases, or genetic profiles, creating competition in highly specialized niches. Emerging technologies like biosensors, nanotechnology, and lab-on-a-chip platforms will be central to next-gen reagent development and will define future competitive advantage.The global IVD reagents market is fiercely competitive, shaped by constant innovation, evolving healthcare needs, and emerging technologies. Major players are leveraging product development, global expansion, strategic collaborations, and digital integration to strengthen their market position. However, this rapidly evolving landscape also presents challenges such as regulatory compliance, cost pressures, and technological disruptions. Looking ahead, companies that prioritize agility, innovation, and localized strategies will be best positioned to lead and thrive in the future of diagnostics.Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are among the key players shaping the global in vitro diagnostics (IVD) reagents market. Abbott stands out as a global leader in this space, offering a comprehensive portfolio of reagent-based solutions across its core laboratory, molecular, point-of-care, and rapid diagnostics segments. Leveraging advanced platforms such as ARCHITECT, Alinity, and ID NOW, Abbott delivers high-throughput and rapid diagnostic capabilities in areas including immunoassays, clinical chemistry, infectious disease detection, and cardiac biomarkers. Its extensive global footprint, strong R&D investments, and established presence in both mature and emerging markets firmly position Abbott as a dominant force in the IVD reagents market.MARKET TRENDS & DRIVERS
Rising Significance of Biomarker Discovery & Companion DiagnosticsThe expanding importance of biomarker discovery and companion diagnostics is reshaping the IVD reagents market. As personalized medicine continues to advance, the demand for high-quality reagents that enable precise biomarker detection and CDx assays is on the rise. Market players who invest in innovative reagent development, form strategic partnerships, and expand into emerging applications will be well-positioned to capitalize on this growing sector. In a time where precision diagnostics is becoming the gold standard, IVD reagent manufacturers have a critical role to play in shaping the future of healthcare.Rise of Point-of-Care (POC) TestingPoint-of-care testing is transforming the diagnostic landscape, leading to a surge in demand for high-quality IVD reagents. With the emergence of decentralized, rapid, and personalized healthcare diagnostics, reagent manufacturers have an opportunity to expand their market presence through innovation. The growing demand for POC testing is being met by companies, that are utilizing advanced molecular reagents, multiplex testing solutions, and digital-friendly diagnostic receptacles.Increasing Demand for Customized Diagnostic Tests & Personalized MedicineThe increasing demand for customized diagnostic tests and personalized medicine is shaping the future of the global IVD reagents market. With advancements in molecular diagnostics, AI-driven testing, and regulatory support for precision medicine, the market is poised for strong growth. Companies that invest in innovation, strategic collaborations, and emerging market expansion will be well-positioned to capitalize on the growing demand for customized IVD solutions.Expansion of AI and Automation in DiagnosticsAs laboratories and healthcare providers increasingly adopt AI-driven systems, the demand for high-quality, automation-friendly IVD reagents will continue to rise. While ongoing technological advancements and strategic collaborations will drive innovation, positioning AI-powered diagnostics as a cornerstone of the future healthcare landscape. Manufacturers that embrace AI-compatible reagent development will be well-positioned to capitalize on this growing market trend.Growing Prevalence of Chronic & Infectious DiseasesThe increasing prevalence of chronic and infectious diseases is a key driver of the global IVD reagents market. The demand for accurate, fast, and cost-effective diagnostic solutions continues to grow, supported by technological advancements and rising healthcare investments. Specifically in emerging economies and personalized medicine applications. Moving forward, innovation in reagent development will play a crucial role in shaping the future of diagnostic testing.Growing Awareness & Early Disease DetectionThe global IVD reagents market is experiencing robust growth due to rising awareness about early disease detection and preventive healthcare. The increasing prevalence of chronic and infectious diseases, coupled with advancements in diagnostic technologies, is driving demand for high-quality IVD reagents. Government initiatives, home-based testing trends, and rapid innovation in molecular diagnostics are further fueling industry expansion.Innovations in Reagent FormulationsAdvances in molecular reagents, lyophilized formulations, automation-friendly solutions, nanotechnology, and eco-friendly alternatives are enhancing diagnostic accuracy, efficiency, and accessibility. Continued R&D and strategic collaborations will accelerate innovation, shaping the future of the IVD industry. As the demand for high-performance diagnostics continues to rise, the market for advanced IVD reagents is poised for substantial growth in the coming years.Expanding Healthcare Infrastructure & Investments in R&DThe global IVD reagents market is witnessing robust growth, fueled by expanding healthcare infrastructure and increased investments in R&D. As healthcare systems worldwide focus on early disease detection and precision diagnostics, the demand for innovative and high-quality reagents will continue to rise. Ongoing technological advancements and strategic collaborations will drive further industry expansion, ultimately improving healthcare outcomes on a global scale.
IVD REAGENTS MARKET GEOGRAPHICAL ANALYSISNorth America holds the largest share of the global IVD reagents market in 2024, accounting for over 38%. The North American IVD reagents market is one of the most advanced and rapidly growing segments in the global healthcare industry. Driven by technological advancements, rising chronic disease prevalence, and increasing demand for rapid and accurate diagnostics, the region holds a significant share of the global market.
The U.S. and Canada, with their well-established healthcare infrastructure and strong regulatory frameworks, are key contributors to industry growth. Moreover, the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases is fueling demand for advanced diagnostic reagents in the region. An aging population requires frequent diagnostic testing for chronic disease management and early disease detection.Europe is the second-largest market in the global IVD reagents market, driven by strong diagnostic research, widespread adoption of IVD regulations (IVDR), and increased funding for healthcare innovation. Germany, France, Russia, and Italy lead in industry share due to robust laboratory infrastructure and government support for early disease detection.
Furthermore, APAC is the fastest-growing market in the global IVD reagents market during the forecast period, driven by rising healthcare investments, increasing prevalence of chronic diseases, and a growing middle-class population. Countries like China, Japan, and India are major contributors due to expanding healthcare access and government initiatives for disease screening. Latin America and the Middle East & Africa are emerging IVD reagents markets with strong potential, driven by rising healthcare investments and the need for improved diagnostics.
Key Attributes:
Report Attribute
Details
No. of Pages
354
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$77.56 Billion
Forecasted Market Value (USD) by 2030
$96.17 Billion
Compound Annual Growth Rate
3.6%
Regions Covered
Global
Market Dynamics
Opportunities & Trends
Rising Significance of Biomarker Discovery & Companion Diagnostics
Rise of Point-Of-Care (Poc) Testing
Increasing Demand for Customized Diagnostic Tests & Personalized Medicine
Expansion of AI and Automation in Diagnostics
Market Growth Enablers
Growing Prevalence of Chronic & Infectious Diseases
Growing Awareness & Early Disease Detection
Innovations in Reagent Formulations
Expanding Healthcare Infrastructure & Investments in R&D
Market Restraints
High Cost of Advanced Diagnostic Tests
Supply Chain Disruptions & Raw Material Shortages
Stringent Regulatory Requirements
Key Company Profiles
Abbott
Danaher
F. Hoffmann La-Roche
Siemens Healthineers
Thermo Fisher Scientific
Other Prominent Vendors
Atomo Diagnostics
Accelerate Diagnostics
Agilent Technologies
altona Diagnostics
Amoy Diagnostics
ARKRAY
AccuBioTech
The Binding Site Group
BD
Bio-Rad Laboratories
BIOMERIEUX
bioLytical Laboratories
Biocartis
Biocept
Biomerica
Bioway Biological Technology
Boule Diagnostics
Cupid
Chembio Diagnostics
CPC Diagnostics
CPM Scientifica
DIALAB GmbH
DiaSorin S.p.A.
Diagon
EDAN Instruments
Illumina
Merck KGaA
MP Biomedicals
OraSure Technologies
QIAGEN
QuidelOrtho
For more information about this report visit https://www.researchandmarkets.com/r/utfeit
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
In-vitro Diagnostics (IVD) Reagents Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

30 minutes ago

• Yahoo

Top Steelers NFL draft prospect LaNorris Sellers passes up huge NIL deal

The top priority of the Pittsburgh Steelers scouting staff this college football season is to sort out what is already shaping up to be an elite quarterback class for the 2026 NFL draft. Thanks to the ridiculous nature of NIL money, the NFL now has another aspect of players to track and that's their loyalty to their team as opposed to making fast money in college football. One of the top quarterback prospects in the upcoming draft is LaNorris Sellers out of South Carolina. News came out about Sellers this week and thanks to some intervention by his dad, Sellers chose to pass up $8 million over two years in NIL money to stay. According to Sellers' dad, there were multiple schools bidding for his services, but he showed maturity and loyalty by staying, which is a huge green flag for an NFL team. Advertisement From a football standpoint, Sellers is poised for a huge breakout season. His athleticism and mobility are already off the charts and as the season progressed, we saw his pocket presence and processing speed improve drastically down the stretch. Sellers and Clemson's Cade Klubnik are my top two options for the Steelers and this move by Sellers just helps his case. This article originally appeared on Steelers Wire: Steelers NFL draft prospect LaNorris Sellers passes up huge NIL deal

Yahoo

31 minutes ago

• Yahoo

Franklin County home listings asked for more money in May - see the current median price here

The median home in Franklin County listed for $364,900 in May, up 1.2% from the previous month's $360,720, an analysis of data from shows. Compared to May 2024, the median home list price increased 13.2% from $324,723. The statistics in this article only pertain to houses listed for sale in Franklin County, not houses that were sold. Information on your local housing market, along with other useful community data, is available at Franklin County's median home was 1,968 square feet, listed at $183 per square foot. The price per square foot of homes for sale is up 2.2% from May 2024. Listings in Franklin County moved briskly, at a median 36 days listed compared to the May national median of 51 days on the market. In the previous month, homes had a median of 38 days on the market. Around 196 homes were newly listed on the market in May, a 7.7% increase from 182 new listings in May 2024. The median home prices issued by may exclude many, or even most, of a market's homes. The price and volume represent only single-family homes, condominiums or townhomes. They include existing homes, but exclude most new construction as well as pending and contingent sales. In Pennsylvania, median home prices were $325,000, a slight increase from April. The median Pennsylvania home listed for sale had 1,708 square feet, with a price of $196 per square foot. Throughout the United States, the median home price was $440,000, a slight increase from the month prior. The median American home for sale was listed at 1,840 square feet, with a price of $234 per square foot. The median home list price used in this report represents the midway point of all the houses or units listed over the given period of time. Experts say the median offers a more accurate view of what's happening in a market than the average list price, which would mean taking the sum of all listing prices then dividing by the number of homes sold. The average can be skewed by one particularly low or high price. The USA TODAY Network is publishing localized versions of this story on its news sites across the country, generated with data from Please leave any feedback or corrections for this story here. This story was written by Ozge Terzioglu. Our News Automation and AI team would like to hear from you. Take this survey and share your thoughts with us. This article originally appeared on Waynesboro Record Herald: Franklin County home listings asked for more money in May - see the current median price here

Yahoo

32 minutes ago

• Yahoo

Trust in AI is growing in finance, especially behind the scenes

This story was originally published on CX Dive. To receive daily news and insights, subscribe to our free daily CX Dive newsletter. A majority of customers trust the use of AI in behind-the-scenes tasks at financial institutions, according to a TD Bank survey conducted by Ipsos released Tuesday. Among the 2,500 U.S. consumers polled, 70% are comfortable with technology being used for fraud detection, and 64% are comfortable with it being used in credit score calculations. Consumers also believe that AI should offer more ease. Two-thirds believe it can expand access to financial tools, and nearly half expect benefits from AI like 24/7 banking access. As consumers have become more familiar with AI tools, their trust in the technology has slowly grown. Nearly 7 in 10 consumers say they are at least somewhat familiar with AI — a finding seen in other surveys, too. Notably, half of consumers trust that AI will provide reliable, competent information, trusting AI just as much as news stations. But consumers are more comfortable with AI in specific use cases and the more complex or sensitive the matter, the more they want to speak to a human or know that a human will be reviewing AI before making any decisions. Consumers are less inclined to want to only use AI when it comes to tasks that one might typically use a financial adviser for, according Ted Paris, EVP, TD Bank AMCB, and head of analytics, intelligence & AI. When it comes to personal finance, 3 in 5 of consumers were comfortable with the idea of using AI financial tools for budgeting and automating savings goals. But less than half were comfortable with more complex tasks like retirement planning and investing. Banks enjoy high consumer trust — more than 4 in 5 consumers trust banks for accurate information. As they deploy AI, it's important that they maintain that, Paris said. 'What's probably the key piece, is creating and enabling and allowing customers and colleagues to feel that they can trust the outcomes of what this capability then generates,' Paris said. One of the ways TD Bank is approaching this is by always having a human in the loop, meaning that the output of an AI solution will be passed through some internal expert before going to a client. 'We need to make sure that first, anything that we're doing is directed toward a particular need,' Paris said. 'We need to make sure that this is going to meet all hurdles that we would set, legal, regulatory, for security and privacy.' Sign in to access your portfolio